Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients.

Heide J, Ribback S, Klatte T, Shariat S, Burchardt M, Dombrowski F, Belldegrun AS, Drakaki A, Pantuck AJ, Kroeger N.

World J Urol. 2019 Sep 13. doi: 10.1007/s00345-019-02930-4. [Epub ahead of print]

PMID:
31520111
2.

Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.

Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde GP.

Eur Urol Oncol. 2019 Mar 9. pii: S2588-9311(19)30028-8. doi: 10.1016/j.euo.2019.02.004. [Epub ahead of print]

PMID:
31412004
3.

To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease.

Pantuck M, McDermott D, Drakaki A.

Cancer. 2019 Jul 18. doi: 10.1002/cncr.32326. [Epub ahead of print] Review.

PMID:
31318445
4.

Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer.

Grivas P, Drakaki A, Friedlander TW, Sonpavde G.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:284-300. doi: 10.1200/EDBK_237449. Epub 2019 May 17.

PMID:
31099684
5.

Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era.

Hui G, Ghafouri SN, Shen J, Liu S, Drakaki A.

Case Rep Oncol Med. 2019 Mar 25;2019:8349793. doi: 10.1155/2019/8349793. eCollection 2019.

6.

Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival.

Lenis AT, Burton CS, Golla V, Pooli A, Faiena I, Johnson DC, Salmasi A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

Urol Oncol. 2019 Sep;37(9):577.e9-577.e16. doi: 10.1016/j.urolonc.2019.03.009. Epub 2019 Mar 28.

PMID:
30930099
7.

Second primary lung cancer in United States Cancer Survivors, 1992-2008.

Donin NM, Kwan L, Lenis AT, Drakaki A, Chamie K.

Cancer Causes Control. 2019 May;30(5):465-475. doi: 10.1007/s10552-019-01161-7. Epub 2019 Mar 21.

PMID:
30900065
8.

Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.

Faiena I, Astrow SH, Elashoff DA, Jain R, Bot A, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A.

Cancer Immunol Immunother. 2019 May;68(5):743-751. doi: 10.1007/s00262-019-02316-w. Epub 2019 Feb 21.

PMID:
30790015
9.

Rapidly progressive neurologic decline and morbilliform rash presenting in a patient with lymphoma.

Ehrlich D, Phan J, Hui G, Drakaki A.

Clin Pract. 2018 Dec 4;8(4):1097. doi: 10.4081/cp.2018.1097. eCollection 2018 Oct 26.

10.

Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better?

Pooli A, Salmasi A, Faiena I, Lenis AT, Johnson DC, Lebacle C, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

Urol Oncol. 2019 Jan;37(1):63-70. doi: 10.1016/j.urolonc.2018.10.018. Epub 2018 Nov 13.

PMID:
30446452
11.

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.

Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR.

JAMA Oncol. 2019 Jan 1;5(1):91-96. doi: 10.1001/jamaoncol.2018.3732.

12.

Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines.

Upfill-Brown A, Lenis AT, Faiena I, Salmasi AH, Johnson DC, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

World J Urol. 2019 Jun;37(6):1157-1164. doi: 10.1007/s00345-018-2506-1. Epub 2018 Sep 28.

PMID:
30267197
13.

Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma.

Salmasi A, Faiena I, Lenis AT, Pooli A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Dec;36(12):527.e13-527.e19. doi: 10.1016/j.urolonc.2018.08.009. Epub 2018 Sep 15.

PMID:
30228094
14.

Next generation T-cell therapy for genitourinary malignancies, part A: Introduction and current state of the art.

Pantuck M, Palaskas N, Drakaki A.

Cancer Treat Res Commun. 2018;17:8-12. doi: 10.1016/j.ctarc.2018.08.001. Epub 2018 Aug 22. Review. No abstract available.

PMID:
30173005
15.

Next generation T-cell therapy for genitourinary malignancies, part B: Overcoming obstacles and future strategies for success.

Pantuck M, Palaskas N, Drakaki A.

Cancer Treat Res Commun. 2018;17:1-7. doi: 10.1016/j.ctarc.2018.08.002. Epub 2018 Aug 17. Review. No abstract available.

PMID:
30170288
16.

Not Just Another Infection.

Zhang B, Master AK, Brown CE, Drakaki A.

Am J Med. 2018 Nov;131(11):e463-e464. doi: 10.1016/j.amjmed.2018.06.029. Epub 2018 Jul 26. No abstract available.

PMID:
30055122
17.

Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.

Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A.

World J Urol. 2019 Jan;37(1):115-123. doi: 10.1007/s00345-018-2355-y. Epub 2018 Jun 1. Review.

PMID:
29858701
18.

Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy.

Faiena I, Salmasi A, Mendhiratta N, Lenis AT, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

World J Urol. 2018 Nov;36(11):1825-1833. doi: 10.1007/s00345-018-2327-2. Epub 2018 May 11.

PMID:
29752514
19.

MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer.

Koutsioumpa M, Chen HW, O'Brien N, Koinis F, Mahurkar-Joshi S, Vorvis C, Soroosh A, Luo T, Issakhanian S, Pantuck AJ, Georgoulias V, Iliopoulos D, Slamon DJ, Drakaki A.

Mol Cancer Ther. 2018 Jul;17(7):1430-1440. doi: 10.1158/1535-7163.MCT-17-1049. Epub 2018 Apr 27.

20.

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P.

Cancer. 2018 May 15;124(10):2115-2124. doi: 10.1002/cncr.31314. Epub 2018 Mar 8.

21.

Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Faiena I, Salmasi A, Pantuck AJ, Drakaki A.

Eur Urol. 2018 Jun;73(6):981. doi: 10.1016/j.eururo.2018.01.023. Epub 2018 Feb 9. No abstract available.

PMID:
29433974
22.

Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy.

Salmasi A, Faiena I, Drakaki A, Pantuck AJ.

Eur Urol. 2018 Jul;74(1):119-121. doi: 10.1016/j.eururo.2018.01.036. Epub 2018 Feb 9. No abstract available.

PMID:
29433972
23.

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.

Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A.

Drug Des Devel Ther. 2018 Jan 23;12:209-215. doi: 10.2147/DDDT.S141491. eCollection 2018. Review.

24.

Trends in urinary diversion after radical cystectomy for urothelial carcinoma.

Bachour K, Faiena I, Salmasi A, Lenis AT, Johnson DC, Pooli A, Drakaki A, Pantuck AJ, Chamie K.

World J Urol. 2018 Mar;36(3):409-416. doi: 10.1007/s00345-017-2169-3. Epub 2018 Jan 3.

PMID:
29299664
25.

The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.

Liu ST, Hui G, Mathis C, Chamie K, Pantuck AJ, Drakaki A.

Clin Genitourin Cancer. 2018 Apr;16(2):e269-e276. doi: 10.1016/j.clgc.2017.10.011. Epub 2017 Nov 3. Review.

PMID:
29199023
26.

Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.

Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Feb;36(2):78.e21-78.e28. doi: 10.1016/j.urolonc.2017.09.030. Epub 2017 Nov 8.

PMID:
29128421
27.

Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.

Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Feb;36(2):79.e19-79.e26. doi: 10.1016/j.urolonc.2017.10.009. Epub 2017 Nov 2.

PMID:
29103965
28.

Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma.

Lenis AT, Donin NM, Faiena I, Salmasi A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun A, Pantuck A, Chamie K.

Urol Oncol. 2018 Jan;36(1):9.e1-9.e9. doi: 10.1016/j.urolonc.2017.09.001. Epub 2017 Oct 20.

PMID:
29066013
29.

Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies.

Way J, Drakaki A, Drexler A, Freeby M.

BMJ Case Rep. 2017 Oct 4;2017. pii: bcr-2017-220415. doi: 10.1136/bcr-2017-220415.

PMID:
28978581
30.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators.

Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12.

PMID:
28916371
31.

Unique microRNA expression in the colonic mucosa during chronic HIV-1 infection.

Fulcher JA, Koukos G, Koutsioumpa M, Elliott J, Drakaki A, Iliopoulos D, Anton PA.

AIDS. 2017 Sep 10;31(14):1925-1934. doi: 10.1097/QAD.0000000000001582.

32.

Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.

Lenis AT, Donin NM, Johnson DC, Faiena I, Salmasi A, Drakaki A, Belldegrun A, Pantuck A, Chamie K.

J Urol. 2018 Jan;199(1):43-52. doi: 10.1016/j.juro.2017.04.092. Epub 2017 May 4. Review.

33.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group.

Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Erratum in: Lancet. 2017 Aug 26;390(10097):848.

34.

Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.

Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT.

Mol Cancer Ther. 2017 Feb;16(2):376-387. doi: 10.1158/1535-7163.MCT-16-0381. Epub 2016 Nov 30.

35.

Immunotherapy for the Treatment of Urothelial Carcinoma.

Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K.

J Urol. 2017 Jan;197(1):14-22. doi: 10.1016/j.juro.2016.02.3005. Epub 2016 Jul 25. Review.

PMID:
27460757
36.

Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification.

Shin DS, Sherry T, Kallen ME, Wong S, Drakaki A.

Case Rep Oncol. 2016 Jun 11;9(2):298-304. doi: 10.1159/000445827. eCollection 2016 May-Aug.

37.

Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.

Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L, Litwin M, Chamie K.

Cancer. 2016 Oct;122(19):3075-86. doi: 10.1002/cncr.30164. Epub 2016 Jul 5.

38.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH.

J Clin Oncol. 2016 Sep 10;34(26):3119-25. doi: 10.1200/JCO.2016.67.9761. Epub 2016 Jun 6.

39.

A functional microRNA library screen reveals miR-410 as a novel anti-apoptotic regulator of cholangiocarcinoma.

Palumbo T, Poultsides GA, Kouraklis G, Liakakos T, Drakaki A, Peros G, Hatziapostolou M, Iliopoulos D.

BMC Cancer. 2016 Jun 3;16:353. doi: 10.1186/s12885-016-2384-0.

40.

Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway.

Drakaki A, Hatziapostolou M, Polytarchou C, Vorvis C, Poultsides GA, Souglakos J, Georgoulias V, Iliopoulos D.

BMC Cancer. 2015 Jul 24;15:542. doi: 10.1186/s12885-015-1562-9.

41.

The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors.

Wainberg ZA, Drakaki A.

Expert Opin Biol Ther. 2015;15(8):1205-20. doi: 10.1517/14712598.2015.1050375. Epub 2015 Jun 12. Review.

PMID:
26066903
42.

MicroRNA-gene signaling pathways in pancreatic cancer.

Drakaki A, Iliopoulos D.

Biomed J. 2013 Sep-Oct;36(5):200-8. doi: 10.4103/2319-4170.119690. Review.

43.

Novel immunotherapies in GU malignancies.

Drakaki A, McDermott DF.

Curr Oncol Rep. 2013 Jun;15(3):224-31. doi: 10.1007/s11912-013-0306-8. Review.

PMID:
23519772
44.

Therapeutically targeting microRNAs in liver cancer.

Drakaki A, Hatziapostolou M, Iliopoulos D.

Curr Pharm Des. 2013;19(7):1180-91. Review.

PMID:
23092338
45.

An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis.

Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M, Iliopoulos D.

Cell. 2011 Dec 9;147(6):1233-47. doi: 10.1016/j.cell.2011.10.043. Erratum in: Cell. 2013 Feb 28;152(5):1196.

46.

MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells.

Lee JJ, Drakaki A, Iliopoulos D, Struhl K.

Oncogene. 2012 Aug 16;31(33):3818-25. doi: 10.1038/onc.2011.543. Epub 2011 Nov 28.

47.

Hypokalemic periodic paralysis due to Graves Disease.

Drakaki A, Habib M, Sweeney AT.

Am J Med. 2009 Dec;122(12):e5-6. doi: 10.1016/j.amjmed.2009.06.016. No abstract available.

PMID:
19958876
48.

MicroRNA Gene Networks in Oncogenesis.

Drakaki A, Iliopoulos D.

Curr Genomics. 2009 Mar;10(1):35-41. doi: 10.2174/138920209787581299.

49.

Epigenetic regulation of hTERT promoter in hepatocellular carcinomas.

Iliopoulos D, Satra M, Drakaki A, Poultsides GA, Tsezou A.

Int J Oncol. 2009 Feb;34(2):391-9.

PMID:
19148473

Supplemental Content

Loading ...
Support Center